Patent ID: 6878363

Claim:
A method for diagnosing a neurological disease involving APP processing and/or beta-amyloid production within a mammalian body comprising: (a) administering a diagnostically effective amount of a radiopharmaceutical secretase inhibitor of APP processing and/or beta-amyloid production; wherein the inhibitor is selected from compounds of: Formula (I-7), (2R,3S) N1-[(3S)-hexahydro-1-(3-phenoxybenzyl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide, its tritiated formula, (I-7T), wherein m is about 2; Formula(I-11), (2R,3S) N1-[(3S)-hexahydro-1-(benzophenon-3-yl)-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide, its tritiated formula (I-11T), wherein m is about 2; Formula (I-43) (2S,3R) N1-(1,3-dihydro-1-methyl-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(allyl)-butanediamide, its tritiated formula (I-43T) Tritiated (2S,3R) N1-[1,3-dihydro-1-methyl-2-oxo-5-(phenyl)-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(n-propyl)-butanediamide, wherein m is about 2; and (b) imaging the area of the patient wherein, the disease is located.